ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 500

Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement

Noortje van Herwaarden1, Chantal Bouman2, Aatke van der Maas3, Ronald F. van Vollenhoven4, Johannes W.J. Bijlsma5, Frank H.J. van den Hoogen6, Alfons A. den Broeder1 and Bart van den Bemt7, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, 4Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 5Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 7Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity in some patients. We evaluated the predictive value of baseline adalimumab and etanercept serum levels and antidrug antibodies for successful dose reduction or discontinuation in patients with RA and low disease activity.

 

Methods

Patients with RA and a stable low disease activity, included in the intervention arm of an 18 months randomised controlled trial (DRESS study) assessing non-inferiority of a dose reduction strategy of adalimumab or etanercept compared to usual care were analysed1. Dose was reduced by stepwise increasing the interval between injections every 3 months until flare or discontinuation of the TNFi. Serum levels of adalimumab or etanercept and antidrug antibodies were measured before start of dose reduction2,3. Receiver-operator-curves (ROC) and optimal cut-off drug serum levels were calculated. A sensitivity analyses was done for timing of serum sampling (days after last injection), per tertile. Sensitivity/specificity of anti-drug antibodies were calculated for successful discontinuation and for successful dose reduction separately.

 

Results

Data was available for 118 of 121 included patients. Mean DAS28-CRP at baseline was 2.2 (SD 0.6). At 18 months follow up TNFi could be stopped in 19% (95%CI 12-27) of patients, the interval increased in 44% (95%CI 35-53) and in 37% (95%CI 29-47) of patients no dose reduction was possible. Mean drug levels and anti-drug antibodies were not different per subgroup (table 1). ROC analyses showed no predictive value of drug levels for successful dose reduction or discontinuation (figure 1). Sensitivity analyses showed no influence of serum sample timing, with the exception of adalimumab trough level (last tertile) predicting successful dose reduction (AUC 0.86, 95% CI 0.58-1.00, optimal cut-off 7.8 μg/ml).

Anti-adalimumab antibodies were detected in 4 patients (10%), and were not predictive for successful discontinuation. No anti-etanercept antibodies were detected.

 

Conclusion

Adalimumab and etanercept serum levels and antidrug antibodies have no predictive value for successful dose reduction or discontinuation in RA patients with low disease activity, with a possible exception of adalimumab trough levels for predicting successful dose reduction.

 

References

1: den Broeder et al. BMC Musculoskelet Disord. 2013 24;14:299

2: Bartelds et al. JAMA 2011;305(14):1460-1468

3: Jamnitski et al. Ann Rheum Dis 2012;71:88-91.

 

 

 

 


Disclosure:

N. van Herwaarden,
None;

C. Bouman,
None;

A. van der Maas,

Roche, MSD, ,

9;

R. F. van Vollenhoven,

Abbott, BMS, GSK, MSD, Pfizer, Roche, UCB ,

2,

Abbott, BMS, GSK, MSD, Pfizer, Roche, UCB ,

5;

J. W. J. Bijlsma,

AbbVie, Roche, Pfizer, MSD, UCB, BMS,

2,

AbbVie, Roche, Pfizer, MSD, UCB, BMS, Jansen,

5;

F. H. J. van den Hoogen,
None;

A. A. den Broeder,
None;

B. van den Bemt,

Roche Pharmaceuticals, Pfizer,

2,

Roche, Pfizer, MSD Abbvie,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-successful-dose-reduction-or-discontinuation-of-adalimumab-or-etanercept-using-serum-drug-levels-and-antidrug-antibody-measurement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies